141 related articles for article (PubMed ID: 15901749)
1. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.
Nakajima M; Fujiki Y; Kyo S; Kanaya T; Nakamura M; Maida Y; Tanaka M; Inoue M; Yokoi T
J Clin Pharmacol; 2005 Jun; 45(6):674-82. PubMed ID: 15901749
[TBL] [Abstract][Full Text] [Related]
2. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer.
Yamaguchi H; Hishinuma T; Endo N; Tsukamoto H; Kishikawa Y; Sato M; Murai Y; Hiratsuka M; Ito K; Okamura C; Yaegashi N; Suzuki N; Tomioka Y; Goto J
Int J Gynecol Cancer; 2006; 16(3):979-85. PubMed ID: 16803472
[TBL] [Abstract][Full Text] [Related]
3. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4.
Taniguchi R; Kumai T; Matsumoto N; Watanabe M; Kamio K; Suzuki S; Kobayashi S
J Pharmacol Sci; 2005 Jan; 97(1):83-90. PubMed ID: 15655291
[TBL] [Abstract][Full Text] [Related]
4. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241
[TBL] [Abstract][Full Text] [Related]
5. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
Fransson MN; Gréen H; Litton JE; Friberg LE
Drug Metab Dispos; 2011 Feb; 39(2):247-55. PubMed ID: 21056987
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.
Gréen H; Khan MS; Jakobsen-Falk I; Åvall-Lundqvist E; Peterson C
J Pharm Sci; 2011 Oct; 100(10):4205-9. PubMed ID: 21702053
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Gréen H; Söderkvist P; Rosenberg P; Mirghani RA; Rymark P; Lundqvist EA; Peterson C
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):130-7. PubMed ID: 19143748
[TBL] [Abstract][Full Text] [Related]
8. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.
Goh BC; Lee SC; Wang LZ; Fan L; Guo JY; Lamba J; Schuetz E; Lim R; Lim HL; Ong AB; Lee HS
J Clin Oncol; 2002 Sep; 20(17):3683-90. PubMed ID: 12202670
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6α-hydroxylation and amodiaquine N-deethylation.
Tsukada C; Saito T; Maekawa M; Mano N; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2015 Oct; 30(5):366-73. PubMed ID: 26427316
[TBL] [Abstract][Full Text] [Related]
10. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8.
García-Martín E; Pizarro RM; Martínez C; Gutierrez-Martín Y; Pérez G; Jover R; Agúndez JA
Pharmacogenomics; 2006 Jun; 7(4):575-85. PubMed ID: 16753005
[TBL] [Abstract][Full Text] [Related]
12. Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation.
Rowbotham SE; Boddy AV; Redfern CP; Veal GJ; Daly AK
Drug Metab Dispos; 2010 Aug; 38(8):1261-6. PubMed ID: 20421446
[TBL] [Abstract][Full Text] [Related]
13. Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes.
Mukai Y; Senda A; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):493-8. PubMed ID: 25424246
[TBL] [Abstract][Full Text] [Related]
14. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population.
Saito Y; Katori N; Soyama A; Nakajima Y; Yoshitani T; Kim SR; Fukushima-Uesaka H; Kurose K; Kaniwa N; Ozawa S; Kamatani N; Komamura K; Kamakura S; Kitakaze M; Tomoike H; Sugai K; Minami N; Kimura H; Goto Y; Minami H; Yoshida T; Kunitoh H; Ohe Y; Yamamoto N; Tamura T; Saijo N; Sawada J
Pharmacogenet Genomics; 2007 Jul; 17(7):461-71. PubMed ID: 17558302
[TBL] [Abstract][Full Text] [Related]
15. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer.
Nakajima Y; Yoshitani T; Fukushima-Uesaka H; Saito Y; Kaniwa N; Kurose K; Ozawa S; Aoyagi N; Kamatani N; Yamamoto N; Kunitoh H; Ohe Y; Tamura T; Yoshida T; Minami H; Saijo N; Katori N; Sawada J
Clin Pharmacol Ther; 2006 Aug; 80(2):179-91. PubMed ID: 16890579
[TBL] [Abstract][Full Text] [Related]
16. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2005 Oct; 97(4):249-56. PubMed ID: 16176562
[TBL] [Abstract][Full Text] [Related]
18. Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials.
Wang Y; Wang M; Qi H; Pan P; Hou T; Li J; He G; Zhang H
Drug Metab Dispos; 2014 Apr; 42(4):782-95. PubMed ID: 24476576
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants.
Václavíková R; Horský S; Simek P; Gut I
Naunyn Schmiedebergs Arch Pharmacol; 2003 Sep; 368(3):200-9. PubMed ID: 12920504
[TBL] [Abstract][Full Text] [Related]
20. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
